UNSPSC 51351523: Hydroxyprogesterone acetate

This classification denotes a therapeutic progestin C23H32O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L124O66YSI, chemically known as 17.alpha.-hydroxy-4-pregnene-3,20-dione acetate, but more generally known as hydroxyprogesterone acetate, which bears US NIH Compound Identifier 9325. European Medicines Agency schedules Hydroxyprogesterone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16436MIG.

Most nations, for tariff and trade purposes, schedule hydroxyprogesterone acetate under HS 29372300 and SITC 54153. As of Q4 2014, HYDROXYPROGESTERONE ACETATE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)OC(=O)C.

UNSPSC 51351523 Hydroxyprogesterone acetate is a Commodity code covering a synthetic progestin pharmaceutical actively procured by state and local health departments, Medicaid agencies, and public health clinics for maternal health programs and hormone replacement therapy. State and local procurement under this code focuses on securing reliable supply of the active pharmaceutical ingredient and finished formulations—typically hydroxyprogesterone caproate (17-OHP-C) injections used in prenatal care to reduce preterm birth risk in high-risk pregnancies, a clinical application that drives recurring demand from public health systems. Issuing bodies include state health departments managing Medicaid pharmaceutical formularies, county health authorities operating maternal health clinics, and regional public health networks coordinating preventive care programs. The code also appears in procurement by state agencies overseeing family planning services and school-based health centers in districts with robust maternal health initiatives.

The source material provides no recent posted opportunities under this code; state and local procurement activity and geographic concentration cannot be characterized from the available data. Buyers evaluating this code should monitor state health department RFPs and cooperative purchasing vehicle announcements—particularly those issued by state pharmaceutical procurement consortia and Medicaid managed-care contracting offices—as maternal health funding initiatives and formulary updates typically drive solicitation cycles. Opportunities in this space tend to cluster around state fiscal-year starts and Medicaid contract renewals, and are often bundled with broader women's health pharmaceutical categories rather than issued as standalone line items.